<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02388321</url>
  </required_header>
  <id_info>
    <org_study_id>2014-11-20-MMC</org_study_id>
    <nct_id>NCT02388321</nct_id>
  </id_info>
  <brief_title>Pediatric Ketamine Study for Pain Management</brief_title>
  <official_title>Comparison of Sub-dissociative Dose Intranasal Ketamine to Intranasal Fentanyl for Treatment of Moderate to Severe Pain in Pediatric Patients Presenting to the Emergency Department: a Prospective, Randomized, Double-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antonios Likourezos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maimonides Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Direct comparison of intranasal sub-dissociative dose ketamine with intranasal fentanyl for
      the treatment of moderate to severe pain in pediatric patients in the emergency department.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intranasal (IN) delivery of analgesic agents provides rapid and convenient drug
      administration without the need for needles. In children, the placement of an intravenous
      line often increases anxiety and pain, requires nursing time, and can be very difficult to
      achieve, so the IN route is particularly advantageous. IN delivery of fentanyl has become
      increasingly more common in pain management for children in many settings, including
      pre-hospital and emergency department (ED) settings. Over the past decade, many studies have
      demonstrated that intranasal fentanyl is as effective as intravenous morphine to treat acute
      moderate to severe pain. Intranasal fentanyl has become standard of care in some pediatric
      EDs with the advantage of avoiding intravenous line placement. However, adverse effects
      attributed to IN fentanyl are similar to those of other opioid analgesics: hypotension,
      sedation, and occasionally respiratory depression. Ketamine is a noncompetitive N-methyl
      D-aspartate (NMDA) receptor antagonist that blocks the release of the excitatory
      neurotransmitter glutamate and provides anesthesia, amnesia, and analgesia by decreasing
      central sensitization and &quot;wind-up&quot; phenomenon. Due to its high lipid solubility, ketamine
      rapidly crosses the blood-brain barrier, provides rapid onset of action (peak concentration
      at 1 minute after intravenous push) and rapid recovery to baseline (duration of action 5-15
      minutes after intravenous push). At sub-dissociative doses, either used as an adjunct to
      opioid analgesics or as a solo agent, ketamine provides effective analgesia while preserving
      airway patency, ventilation, and cardiovascular stability.

      Ketamine has been less studied for pain management, however it has been safely used via
      different routes of administration in children. Studies dating back to 1990's use ketamine at
      doses as high as 6 mg/kg intranasally in children for pre-medication prior to surgery or for
      sedation with little or no reported adverse effects. A hospital in Australia is currently
      conducting a clinical trial comparing IN fentanyl 1.5 ug/kg to IN ketamine 1mg/kg for the
      treatment of pain caused by isolated musculoskeletal injury. The intention of our study is
      similar to this, however the investigators will not limit the patients to those with only
      musculoskeletal pain and a more simplified pain scale will be used.

      To assess pain, the investigators will use the standard pain scale that is currently used in
      our Pediatric ED in order to minimize the need to re-train any of our staff with a different
      pain scale. The scale incorporates the Numerical rating scale (0-10 scale; NRS) and the
      Wong-Baker faces pain scale (6 faces corresponding to 0,2,4,6,8,10; WBS). While prior studies
      have used different pain scales, primarily the visual analog scale (VAS), the scales that the
      investigator currently use have been validated in children in 2009.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Patients meeting inclusion criteria was low, and PI went to another institution.
  </why_stopped>
  <start_date type="Actual">May 1, 2015</start_date>
  <completion_date type="Actual">October 14, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score at 30 Minutes</measure>
    <time_frame>30 minutes</time_frame>
    <description>An 11 point Likert Visual Analog Scale with 0 being no pain, 5 being moderate pain and 10 being very severe pain was verbally administered to the patient at 30 minutes post administration of analgesia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events at 30 Minutes</measure>
    <time_frame>30 minutes</time_frame>
    <description>The patient were asked at 30 minutes post administration of analgesia if they experienced any side effects like nausea, vomiting, headache etc.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.</description>
    <arm_group_label>Fentanyl</arm_group_label>
    <other_name>Fetanyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children aged 3-17,

          -  weighing less than 50kg

          -  present to the pediatric ED with moderate-severe acute pain (defined as pain greater
             than or equal to 6/10).

          -  Treating physician determines the patient to require opioid analgesia.

        Exclusion Criteria:

          -  Children with facial trauma or any abnormal nasal anatomy;

          -  developmentally delayed children;

          -  children with head trauma/increased intracranial pressure (ICP);

          -  children with known allergy to fentanyl or ketamine;

          -  children who are unable to provide pain scale assessment;

          -  children with chronic pain of greater than 4 weeks;

          -  Pregnant females;

          -  and children with a Glasgow Coma Scale (GCS)&lt;15.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabina Zavolkovskaya, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergey Motov, MD</last_name>
    <role>Study Director</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Marshall, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Andolfatto G, Willman E, Joo D, Miller P, Wong WB, Koehn M, Dobson R, Angus E, Moadebi S. Intranasal ketamine for analgesia in the emergency department: a prospective observational series. Acad Emerg Med. 2013 Oct;20(10):1050-4. doi: 10.1111/acem.12229.</citation>
    <PMID>24127709</PMID>
  </reference>
  <reference>
    <citation>Borland M, Jacobs I, King B, O'Brien D. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Ann Emerg Med. 2007 Mar;49(3):335-40. Epub 2006 Oct 25.</citation>
    <PMID>17067720</PMID>
  </reference>
  <reference>
    <citation>Borland ML, Clark LJ, Esson A. Comparative review of the clinical use of intranasal fentanyl versus morphine in a paediatric emergency department. Emerg Med Australas. 2008 Dec;20(6):515-20. doi: 10.1111/j.1742-6723.2008.01138.x. Erratum in: Emerg Med Australas. 2009 Apr;21(2):166. Dosage error in article text. Emerg Med Australas. 2009 Jun;21(3):246. Dosage error in article text.</citation>
    <PMID>19125831</PMID>
  </reference>
  <reference>
    <citation>Borland M, Milsom S, Esson A. Equivalency of two concentrations of fentanyl administered by the intranasal route for acute analgesia in children in a paediatric emergency department: a randomized controlled trial. Emerg Med Australas. 2011 Apr;23(2):202-8. doi: 10.1111/j.1742-6723.2011.01391.x. Epub 2011 Feb 8.</citation>
    <PMID>21489168</PMID>
  </reference>
  <reference>
    <citation>Garra G, Singer AJ, Taira BR, Chohan J, Cardoz H, Chisena E, Thode HC Jr. Validation of the Wong-Baker FACES Pain Rating Scale in pediatric emergency department patients. Acad Emerg Med. 2010 Jan;17(1):50-4. doi: 10.1111/j.1553-2712.2009.00620.x. Epub 2009 Dec 9.</citation>
    <PMID>20003121</PMID>
  </reference>
  <reference>
    <citation>Goldman RD: Intranasal drug delivery for children with acute illness. Curr Drug Ther 2006, 1(1):127-130.</citation>
  </reference>
  <reference>
    <citation>Grassin-Delyle S, Buenestado A, Naline E, Faisy C, Blouquit-Laye S, Couderc LJ, Le Guen M, Fischler M, Devillier P. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther. 2012 Jun;134(3):366-79. doi: 10.1016/j.pharmthera.2012.03.003. Epub 2012 Mar 23. Review.</citation>
    <PMID>22465159</PMID>
  </reference>
  <reference>
    <citation>Graudins A, Meek R, Egerton-Warburton D, Seith R, Furness T, Chapman R. The PICHFORK (Pain InCHildren Fentanyl OR Ketamine) trial comparing the efficacy of intranasal ketamine and fentanyl in the relief of moderate to severe pain in children with limb injuries: study protocol for a randomized controlled trial. Trials. 2013 Jul 10;14:208. doi: 10.1186/1745-6215-14-208.</citation>
    <PMID>23842536</PMID>
  </reference>
  <reference>
    <citation>Holdgate A, Cao A, Lo KM. The implementation of intranasal fentanyl for children in a mixed adult and pediatric emergency department reduces time to analgesic administration. Acad Emerg Med. 2010 Feb;17(2):214-7. doi: 10.1111/j.1553-2712.2009.00636.x.</citation>
    <PMID>20070272</PMID>
  </reference>
  <reference>
    <citation>Karlsen AP, Pedersen DM, Trautner S, Dahl JB, Hansen MS. Safety of intranasal fentanyl in the out-of-hospital setting: a prospective observational study. Ann Emerg Med. 2014 Jun;63(6):699-703. doi: 10.1016/j.annemergmed.2013.10.025. Epub 2013 Nov 22.</citation>
    <PMID>24268523</PMID>
  </reference>
  <reference>
    <citation>Miner JR, Kletti C, Herold M, Hubbard D, Biros MH. Randomized clinical trial of nebulized fentanyl citrate versus i.v. fentanyl citrate in children presenting to the emergency department with acute pain. Acad Emerg Med. 2007 Oct;14(10):895-8.</citation>
    <PMID>17898251</PMID>
  </reference>
  <reference>
    <citation>National Institute of Clinical Studies: Emergency care acute pain management manual, National Health and Medical Research Council. Canberra, Australia: ACT; 2011.</citation>
  </reference>
  <reference>
    <citation>Pag√© MG, Katz J, Stinson J, Isaac L, Martin-Pichora AL, Campbell F. Validation of the numerical rating scale for pain intensity and unpleasantness in pediatric acute postoperative pain: sensitivity to change over time. J Pain. 2012 Apr;13(4):359-69. doi: 10.1016/j.jpain.2011.12.010. Epub 2012 Mar 15.</citation>
    <PMID>22424915</PMID>
  </reference>
  <reference>
    <citation>Rickard C, O'Meara P, McGrail M, Garner D, McLean A, Le Lievre P. A randomized controlled trial of intranasal fentanyl vs intravenous morphine for analgesia in the prehospital setting. Am J Emerg Med. 2007 Oct;25(8):911-7.</citation>
    <PMID>17920976</PMID>
  </reference>
  <reference>
    <citation>Saunders M, Adelgais K, Nelson D. Use of intranasal fentanyl for the relief of pediatric orthopedic trauma pain. Acad Emerg Med. 2010 Nov;17(11):1155-61. doi: 10.1111/j.1553-2712.2010.00905.x.</citation>
    <PMID>21175512</PMID>
  </reference>
  <reference>
    <citation>Yeaman F, Meek R, Egerton-Warburton D, Rosengarten P, Graudins A. Sub-dissociative-dose intranasal ketamine for moderate to severe pain in adult emergency department patients. Emerg Med Australas. 2014 Jun;26(3):237-42. doi: 10.1111/1742-6723.12173. Epub 2014 Apr 8.</citation>
    <PMID>24712757</PMID>
  </reference>
  <reference>
    <citation>Yeaman F, Oakley E, Meek R, Graudins A. Sub-dissociative dose intranasal ketamine for limb injury pain in children in the emergency department: a pilot study. Emerg Med Australas. 2013 Apr;25(2):161-7. doi: 10.1111/1742-6723.12059. Epub 2013 Mar 20.</citation>
    <PMID>23560967</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <results_first_submitted>March 26, 2018</results_first_submitted>
  <results_first_submitted_qc>May 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 8, 2018</results_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>Antonios Likourezos</investigator_full_name>
    <investigator_title>Research Manager</investigator_title>
  </responsible_party>
  <keyword>Analgesia</keyword>
  <keyword>pediatrics</keyword>
  <keyword>pain management</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketamine</title>
          <description>intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
Ketamine: intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.</description>
        </group>
        <group group_id="P2">
          <title>Fentanyl</title>
          <description>intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
Fentanyl: intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine</title>
          <description>intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
Ketamine: intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.</description>
        </group>
        <group group_id="B2">
          <title>Fentanyl</title>
          <description>intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
Fentanyl: intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.8" spread="2.5"/>
                    <measurement group_id="B2" value="9.6" spread="2.9"/>
                    <measurement group_id="B3" value="9.7" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Score at 30 Minutes</title>
        <description>An 11 point Likert Visual Analog Scale with 0 being no pain, 5 being moderate pain and 10 being very severe pain was verbally administered to the patient at 30 minutes post administration of analgesia.</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
Ketamine: intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.</description>
          </group>
          <group group_id="O2">
            <title>Fentanyl</title>
            <description>intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
Fentanyl: intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score at 30 Minutes</title>
          <description>An 11 point Likert Visual Analog Scale with 0 being no pain, 5 being moderate pain and 10 being very severe pain was verbally administered to the patient at 30 minutes post administration of analgesia.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" spread="2.6"/>
                    <measurement group_id="O2" value="2.09" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events at 30 Minutes</title>
        <description>The patient were asked at 30 minutes post administration of analgesia if they experienced any side effects like nausea, vomiting, headache etc.</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
Ketamine: intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.</description>
          </group>
          <group group_id="O2">
            <title>Fentanyl</title>
            <description>intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
Fentanyl: intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events at 30 Minutes</title>
          <description>The patient were asked at 30 minutes post administration of analgesia if they experienced any side effects like nausea, vomiting, headache etc.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ketamine</title>
          <description>intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
Ketamine: intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.</description>
        </group>
        <group group_id="E2">
          <title>Fentanyl</title>
          <description>intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
Fentanyl: intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizzines</sub_title>
                <description>Dizziness</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small Sample size</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sergey Motov, MD (Prinicipal Investigator)</name_or_title>
      <organization>Maimonides Medical Center</organization>
      <phone>718-283-8693</phone>
      <email>smotov@maimonidesmed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

